• 1
    Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81106.
  • 2
    UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 104454.
  • 3
    Silagy CA, NcNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in healthy elderly population. Clin Pharmacol Ther 1993; 54: 849.
  • 4
    Patrono C, Coller B, Dalen JE, et al. Avoidance of a major vascular event in 50 patients per 1,000 patients with unstable angina who has been treated for 6 months. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S63S.
  • 5
    Food and Drug Administration. Food and Drug Administration Web Site. Drug Approvals for November 1997. Available at:
  • 6
    Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199209.
  • 7
    CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic event (CAPRIE). Lancet 1996; 348: 132939.
  • 8
    Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. Br Med J 1988; 297: 101721.
  • 9
    Robinson MG, Friffin JW, Bower H, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989; 34: 4248.
  • 10
    Yeomans ND, Tulassay Z, Juhasz L, et al. Omeprazole compared with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 71926.
  • 11
    Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 4439.
  • 12
    Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 28797.
  • 13
    Sihigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 1998; 286: 138390.
  • 14
    Aster RH. The study of platelet kinetics with 51Cr-labeled platelets. In: PaulusJM, ed. Platelet Kinetics. Amsterdam: North Holland, 1971: 31723.
  • 15
    Rockall TA, Logan RFA, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 31621.
  • 16
    Wong SK, Yu LM, Lau JY, et al. Prediction of therapeutic failure after adrenaline injection plus heater probe treatment in patients with bleeding peptic ulcer. Gut 2002; 50: 3225.
  • 17
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 34960.
  • 18
    Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 136975.
  • 19
    Yusuf S, Zhao F, Mehta ST, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. N Engl J Med 2001; 345: 494502.